25.03.2013 Views

Canada - World Health Organization Regional Office for Europe

Canada - World Health Organization Regional Office for Europe

Canada - World Health Organization Regional Office for Europe

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Health</strong> systems in transition <strong>Canada</strong> 67<br />

To understand the underlying health cost drivers, it is essential to separate<br />

health spending by service programmes or functions, and then examine the<br />

impact of health-specific inflation, increased utilization and ageing. From the<br />

1980s until the mid-2000s, prescription drugs were the fastest growing category<br />

of health expenditure, and most of this growth was due to a combination of<br />

increased utilization, the introduction of new drug therapies and higher prices.<br />

In this respect, <strong>Canada</strong> has had among the highest generic drug prices in<br />

the world (perhaps in part due to the lack of generic price regulation at the<br />

national level). In contrast, factory gate prices of branded prescription drug are<br />

regulated by the PMPRB while CADTH provides provincial governments with<br />

a centralized drug assessment and review process <strong>for</strong> new prescription drugs<br />

(Romanow, 2002; McMahon, Morgan & Mitton, 2006).<br />

Since 2005, there has been an acceleration in spending on physicians driven<br />

more by increases in remuneration than volume. Hospital expenditures have<br />

also grown rapidly due mainly to increases in staffing levels, compensation and<br />

the increased use of advanced technologies, including advanced diagnostics.<br />

In sharp contrast, the growth in prescription drug spending in recent years<br />

has been largely due to increases in utilization as opposed to price, due to the<br />

maturing of patents as well as a slowing in the rate of new drugs coming on the<br />

market relative to previous periods (CIHI, 2011b).<br />

3.2 Sources of revenue and financial flows<br />

The principal source of health system finance is taxation by the F/T/P<br />

governments (see Fig. 3.6). Since medicare services are exempt from patient<br />

payment at the point of service, they are entirely financed by government<br />

revenues mainly at the provincial level. The sources of funding <strong>for</strong> other health<br />

goods and services are derived from a combination of taxation, OOP payments<br />

and PHI. The vast majority of PHI comes in the <strong>for</strong>m of employment-based<br />

insurance that employees are required to take on as part of a given package<br />

of remuneration and benefits. Social insurance <strong>for</strong>ms the smallest portion of<br />

health funding and is largely used <strong>for</strong> health benefits <strong>for</strong> workplace injuries or<br />

ailments available under workers’ compensation schemes in the provinces and<br />

territories (see section 3.3.2).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!